摘要
背景:SIRTUIN1是组蛋白和非组蛋白脱乙酰作用的表观遗传酶。 它主要作用于代谢传感器,该传感器响应于通过脱乙酰基来改变能量状态。非常关键的转录因子和辅助因子。通过这种方式,Sirtuin 1可以调节线粒体功能和生物发生、氧化应激、炎症、凋亡和细胞衰老。干扰所有这些现象都促进了糖尿病并发症的发病。这些疾病与慢性高血糖有着不可分割的联系,而高血糖具有很强的表观遗传决定因素。 目的:总结Sirtuin 1在糖尿病并发症发生、发展和治疗中的作用。 方法:我们查阅了大量文献,描述了Sirtuin 1在病理生理和治疗各种糖尿病并发症方面的重要性,直到2017。我们关注的是这个例子S合成和天然化合物-介导的Sirtuin 1上调与Sirtuin 1相关的表观遗传学。 结果:Sirtuin 1的减少与内皮功能障碍和代谢记忆有关,是微血管和大血管并发症发生的基础。谢绝Sirtuin 1也参加糖尿病睾丸和勃起功能障碍。Sirtuin 1通过天然存在的抗氧化剂和抗炎物质如白藜芦醇、反式δ-viniferin、维生素D等而升高。西轻微的,Sirtuin 1水平在治疗后会增加标准的高血糖(二甲双胍,exenatide,liraglutide),降压(沙坦),降脂(纤维蛋白,他汀类)和抗凝血剂。药物。在表观遗传学方面,许多miRNAs触发Sirtuin 1的减少,这进一步促进了Sirtuin 1的组蛋白乙酰化--这与糖尿病基因有关。 结论:有证据表明,Sirtuin 1上调可能是治疗糖尿病并发症发展和进展的有效方法。
关键词: SIRT 1,胰岛素抵抗,糖尿病,糖尿病并发症,SIRT 1相关表观遗传学,SIRT 1靶向药物。
Current Medicinal Chemistry
Title:SIRT1 as a Therapeutic Target in Diabetic Complications
Volume: 25 Issue: 9
关键词: SIRT 1,胰岛素抵抗,糖尿病,糖尿病并发症,SIRT 1相关表观遗传学,SIRT 1靶向药物。
摘要: Background: Sirtuin1 is an epigenetic enzyme involved in histone and nonhistone protein deacetylation. It acts primarily as a metabolic sensor, which responses to changing energy status by deacetylating crucial transcription factors and cofactors. In this way, Sirtuin1 regulates mitochondrial function and biogenesis, oxidative stress, inflammation, apoptosis and cellular senescence. Disturbance of all of these phenomena promotes the pathogenesis of diabetic complications. These disorders are inseparably connected with chronic hyperglycemia, which possesses a strong epigenetic determinant.
Objective: To summarize the contemporary knowledge regarding the role of Sirtuin1 in the development, progression and therapy of diabetic complications.
Methods: We extensively searched literature describing the importance of Sirtuin1 in pathophysiology and treatment of all kinds of diabetic complications till September 2017. We focused on the examples of synthetic and natural compounds-mediated Sirtuin1 upregulation along with Sirtuin1-associated epigenetics.
Results: Reduction of Sirtuin1 is implicated in endothelial dysfunction and metabolic memory, underlying the development of micro- and macrovascular complications. Declined Sirtuin1 also participates in diabetic testicular and erectile dysfunction. Sirtuin1 is elevated by naturally occurring anti-oxidant and anti-inflammatory compounds such as resveratrol, trans-δ-viniferin, vitamin D and more. Similarly, Sirtuin1 level increases after treatment with standard antihyperglycemic (metformin, exenatide, liraglutide), antihypertensive (sartans), lipid-lowering (fibrates, statins) and anticoagulant (fidarestat) drugs. Regarding epigenetics, a number of miRNAs trigger Sirtuin1 decrease, which further contributes to histone acetylation of Sirtuin1-regulated and relevant for diabetes genes.
Conclusion: Evidence strongly suggest that Sirtuin1 upregulation may serve as a potent therapeutic approach against development and progression of diabetic complications.
Export Options
About this article
Cite this article as:
SIRT1 as a Therapeutic Target in Diabetic Complications, Current Medicinal Chemistry 2018; 25 (9) . https://dx.doi.org/10.2174/0929867324666171107103114
DOI https://dx.doi.org/10.2174/0929867324666171107103114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Compounds, Epigenetic Modifications and Metabolic Diseases
Current Chemical Biology The Proteasome in Health and Disease
Current Pharmaceutical Design Influence of Essential Trace Minerals and Micronutrient Insufficiencies on Harmful Metal Overload in a Mongolian Patient with Multiple Sclerosis
Current Aging Science Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine The Science of Hypoglycemia in Patients with Diabetes
Current Diabetes Reviews Improving Antihypertensive Agent Selection to Promote Nephroprotection
Current Hypertension Reviews Intracellular and Extracellular Zinc Detection by Organic Fluorescent Receptor
Current Organic Chemistry Nanoemulsions for Intranasal Delivery of Riluzole to Improve Brain Bioavailability: Formulation Development and Pharmacokinetic Studies
Current Drug Delivery Commentary((Research Highlights)(Amyotrophic Lateral Sclerosis: Targeting the Body’s Energy Engine))
CNS & Neurological Disorders - Drug Targets Discovery of Potential Sorbitol Dehydrogenase Inhibitors from Virtual Screening
Medicinal Chemistry Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Modelling of Aldose Reductase Inhibitory Activity of Pyrrol-1-yl-acetic Acid Derivatives by Means of Multivariate Statistics
Medicinal Chemistry In-vitro Studies on α-Amylase, α-Glucosidase and Aldose Reductase Inhibitors found in Endophytic Fungi Isolated from Ocimum sanctum
Current Enzyme Inhibition Prepubertal IGF-1 and Possible Relation with Physical Features of Growth and Type 1 Diabetes Mellitus
Current Diabetes Reviews A Comprehensive Review on Recently Detected Herbal Phytoactives Having Anti-Diabetic Potential for Various Diabetes-Related Complications
Current Traditional Medicine “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
Current Alzheimer Research Unfolded Protein Response in Chronic Obstructive Pulmonary Disease: Smoking, Aging and Disease: A SAD Trifecta
Current Molecular Medicine The Antidiabetic PPARγ Ligands: An Update on Compounds in Development
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents